Abstracts Archive - Page 315 of 2607 - ACR Meeting Abstracts

Abstract Number: 0166 • ACR Convergence 2024
Limitations in Activities of Daily Living Among Individuals with SLE
Laura Plantinga¹, Jinoos Yazdany², Courtney Hoge³, Charmayne M. Dunlop-Thomas⁴ and Patti Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁵UCSF, San Rafael, CA
Background/Purpose: A better understanding of the capacity of individuals with SLE to perform routine daily life tasks is needed to effectively support the independence and…
Abstract Number: 0163 • ACR Convergence 2024
Modification of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis, Clinically Amyopathic Dermatomyositis, and Immune-mediated Necrotizing Myopathy
Ching Chung¹, Yusra Hasan², Rajesh Gopalarathinam³, shiri keret⁴, Dana Ascherman⁵, Siamak Mogahadam⁶, Chester Oddis⁶ and Rohit Aggarwal⁷, ¹UPMC McKeesport, Pittsburgh, PA, ²CHI health Creighton university medical center, Omaha, NE, ³Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, ⁴Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The 2017 ACR/EULAR classification criteria for idiopathic inflammatory myopathies (IIM) currently used in myositis clinical trials/research demonstrated 87% sensitivity and 82% specificity for a…
Abstract Number: 0158 • ACR Convergence 2024
Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Karis Lee¹, Min Kyung Lee², David Alfego³, Kristen Clark⁴ and Stanley Naides⁵, ¹Labcorp, Orlando, FL, ²Labcorp, San Diego, CA, ³Labcorp, Carlsbad, CA, ⁴Labcorp, Raleigh, NC, ⁵Labcorp, Dana Point, CA
Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
Abstract Number: 0174 • ACR Convergence 2024
A Nationwide Analysis of Gender and Racial Disparities in Patients with Systemic Sclerosis and Acute Coronary Syndrome
Omair Khan¹, Kundan Jana², Azka Naeem², Syed Mujtaba Baqir², Marlon Rivera Boadla², Muhammad Hashim khan² and Vijay Shetty², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune condition characterized by widespread skin fibrosis and/or end-organ damage. Previous studies have reported variable outcomes of the disease…
Abstract Number: 0145 • ACR Convergence 2024
Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Leila Milanfar¹, Jinoos Yazdany², Amanda Eudy³, Courtney Hoge⁴, Charmayne M. Dunlop-Thomas⁵, Patti Katz⁶ and Laura Plantinga⁷, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Duke University, Raleigh, NC, ⁴Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁶UCSF, San Rafael, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Measurement of the extent to which individuals move throughout their community and participate in social activities (“community mobility”) can provide a snapshot of how…
Abstract Number: 0180 • ACR Convergence 2024
Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)
Brandon Jackson¹, Maria Dall'Era², Saira Sheikh³, Xueting Zhang⁴, Taylor Irons⁵, Claire Finney⁶, Taylor Adjei⁷, Jennifer Meriwether⁷, Caroline Donovan⁸, Carla Menezes⁹ and Stacie Bell¹⁰, ¹Lupus Research Alliance / Lupus Therapeutics, Miami, FL, ²UCSF, Corte Madera, CA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Weill Cornell, New York, NY, ⁵Lupus Research Alliance / Lupus Therapeutics, Houston, ⁶Lupus Research Alliance / Lupus Therapeutics, Birmingham, AL, ⁷Lupus Research Alliance / Lupus Therapeutics, New York, NY, ⁸Lupus Research Alliance / Lupus Therapeutics, Arlington, VA, ⁹Lupus Research Alliance / Lupus Therapeutics, Brooklyn, NY, ¹⁰Lupus Therapeutics, Lakewood, CO
Background/Purpose: Racial and ethnic minority groups face higher lupus prevalence and severity and remain inadequately represented in lupus clinical trials. Lupus Therapeutics, the clinical affiliate…
Abstract Number: 0185 • ACR Convergence 2024
New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities
Jonathan Katz¹, Ang Yu², Felix Elwert², Robert Greenlee³, David Gazeley⁴, Ann Rosenthal⁵, Jenna Cormier⁵, Bryn Sutherland⁵, Shalvi Parikh⁶, Yiran Jiang⁷ and Christie Bartels⁸, ¹University of Wisconsin Hospitals and Clinics, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³Marshfield Clinical Research Institute, Marshfield, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mississippi Delta Family Medicine Residency, Greenville, MS, ⁷Annapolis Rheumatology, Washington, DC, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) disproportionally affects minoritized populations. SLE damage, assessed by SLICC/ACR Damage Index (SDI), is higher in Black than in White US…
Abstract Number: 0170 • ACR Convergence 2024
Association of General Physical Functioning, Valued Life Activity (VLA) Disability, and Use of Accommodations with Depressive Symptoms Among Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Laura Plantinga², Maria Dall'Era³, Kamil Barbour⁴, Kurt Greenlund⁴ and Jinoos Yazdany⁵, ¹UCSF, San Rafael, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, Corte Madera, CA, ⁴CDC, Alpharetta, GA, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Physical functioning (PF) is usually assessed generally in SLE rather than as difficulty performing specific activities, and measurements rarely incorporate accommodations (ACCs) that may…
Abstract Number: 0172 • ACR Convergence 2024
Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies
Brandon Levian¹, Charlotte Botz², Jason Chwa², Sophie Grove², Vignesh Ravi², Branden Ireifej³, daniel arkfeld⁴, Diana Hanna², Jenny Hu² and Binh Ngo², ¹Keck School of Medicine, Beverly Hills, CA, ²Keck School of Medicine, Los Angeles, ³LAGMC/Keck School of Medicine, Los Angeles, CA, ⁴Keck Medical Center of USC, RANCHO PALOS VERDES, CA
Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
Abstract Number: 0188 • ACR Convergence 2024
Social Support in African American Women with and Without Systemic Lupus Erythematosus (SLE)
Sarah Smith¹, Chloe Mattila¹, Charmayne M. Dunlop-Thomas², Lusawasra King³, Lori Ann Ueberroth³, Edith Williams⁴, S. Sam Lim⁵, Diane Kamen³, Bethany Wolf³ and Paula Ramos³, ¹Medical University of South Carolina, Charleston, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ³Medical University of South Carolina, Charleston, SC, ⁴University of Rochester School of Medicine and Dentistry, Rochester, ⁵Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately impacts African American women. However, this health disparity population continues to be underrepresented in research. Research suggests that social…
Abstract Number: 0161 • ACR Convergence 2024
Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022
malay rathod¹, Eva Kalra², Rafael Sanchez-Dopazo,³, Janmay Vala⁴, Saif Syed⁵, Akhilesh Sharma⁶, Ashwinikumar Shandilya⁷, Asmita Gera⁸, Mohit Lakkimsetti⁹, Juhi Patel¹⁰, VISHRANT AMIN¹¹ and Hardik Desai¹², ¹Monmouth Medical Center, Rutgers University, Ewing, NJ, ²Trident Medical Cente, Charleston, SC, ³Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁶Adesh Institute of Medical Sciences and Research, Bhatinda, India, ⁷Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁸Tianjin medical University, Tianjin, China, Tianjin, Tianjin, China (People's Republic), ⁹Mamata Medical College,Khammam, Khammam, Telangana, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹¹GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹²Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) poses a significant and escalating health challenge across Latin America and the Caribbean (LAC), driven by demographic shifts, lifestyle factors, and varying…
Abstract Number: 0182 • ACR Convergence 2024
Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Patricia Nogueira De Sa¹, Stephanie Wirtshafter¹, Abdallah Geara² and Kimberly DeQuattro², ¹University of Pennsylvania, Pennsylvania, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune condition that disproportionally affects individuals from racial and ethnic minority groups with more than 95%…
Abstract Number: 0187 • ACR Convergence 2024
Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
Abstract Number: 0184 • ACR Convergence 2024
Improving Age Disparities in Contraceptive Counseling in Women with Lupus: A Quality Improvement Initiative
Hillary Weisleder¹, Chinenye Osuorji², Melissa Fazzari³, Ying Jin² and Bibi Ayesha², ¹Montefiore Einstein, New York, NY, ²Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus is an autoimmune disease primarily affecting women of reproductive age. Lupus confers an increased risk of adverse maternal fetal outcomes, and pre-pregnancy planning…
Abstract Number: 0140 • ACR Convergence 2024
Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas
Fabiola Atzeni¹, Fabio Cacciapaglia², Elena Bartoloni Bocci³, Matteo Piga⁴, Garifallia Sakellariou⁵, Ombretta Viapiana⁶, Alessandro Giollo⁷, SIMONE PARISI⁸, Maria Sole Chimenti⁹, Ennio Giulio Favalli¹⁰, Addolorata Corrado¹¹, Eleonora Celletti¹², Ivan Giovannini¹³, Serena Guiducci¹⁴, Elisa Gremese¹⁵, Andreina Manfredi¹⁶, Francesca Romana Spinelli¹⁷ and Gian Luca Erre¹⁸, and "Cardiovascular Obesity and Rheumatic DISeaases" Study Group of the Italian Society of Rheumatology, ¹University of Messina, Italy, Messina, Italy, ²Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ³Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁴Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁵Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁶Rheumatology Unit, University of Verona, Verona, Italy, ⁷Azienda Ospedale Università Padova, Padova, Padua, Italy, ⁸Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ¹⁰ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹¹Rheumatology Unit, University of Foggia, Foggia, Italy, ¹²Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴University of Florence, Pistoia, Italy, ¹⁵Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁶University of Modena and Reggio Emilia, Modena, ¹⁷Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁸Rheumatology Unit - University of Sassari, Sassari, Italy
Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].